The reovirus μ2 C-terminal loop inversely regulates NTPase and transcription functions versus binding to factory-forming μNS and promotes replication in tumorigenic cells.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
26 04 2021
Historique:
entrez: 4 3 2021
pubmed: 5 3 2021
medline: 5 3 2021
Statut: ppublish

Résumé

Wild type reovirus serotype 3 'Dearing PL strain' (T3wt) is being heavily evaluated as an oncolytic and immunotherapeutic treatment for cancers. Mutations that promote reovirus entry into tumor cells were previously reported to enhance oncolysis; herein we aimed to discover mutations that enhance the post-entry steps of reovirus infection in tumor cells. Using directed evolution, we identified that reovirus variant T3v10

Identifiants

pubmed: 33658345
pii: JVI.02006-20
doi: 10.1128/JVI.02006-20
pmc: PMC8139653
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 American Society for Microbiology.

Références

Virology. 2015 Sep;483:291-301
pubmed: 26004253
J Virol. 2020 Jan 31;94(4):
pubmed: 31748391
J Biol Chem. 2004 Mar 5;279(10):8547-57
pubmed: 14670972
J Virol. 2000 Apr;74(7):2981-9
pubmed: 10708412
J Virol Methods. 2000 Oct;90(1):59-67
pubmed: 11011081
Proc Natl Acad Sci U S A. 1963 Aug;50:268-75
pubmed: 14060643
J Virol. 2015 Apr;89(8):4319-34
pubmed: 25653434
Sci Rep. 2017 Sep 7;7(1):10873
pubmed: 28883463
J Virol. 2012 Feb;86(4):2302-11
pubmed: 22156521
Virology. 2007 Aug 1;364(2):301-16
pubmed: 17451769
J Virol. 2005 Jul;79(13):7967-78
pubmed: 15956543
Cancer Res. 2010 Jun 15;70(12):4912-21
pubmed: 20501842
J Virol. 2004 May;78(10):5528-30
pubmed: 15113934
J Virol. 2005 May;79(10):6194-206
pubmed: 15858004
Mol Ther. 2007 Aug;15(8):1522-30
pubmed: 17457318
J Virol. 2012 Jul;86(13):7403-13
pubmed: 22532697
Biol Cell. 2005 Feb;97(2):147-72
pubmed: 15656780
J Virol. 1998 Oct;72(10):8354-7
pubmed: 9733883
Oncolytic Virother. 2018 Jun 14;7:53-63
pubmed: 29942799
PLoS One. 2017 Sep 7;12(9):e0184356
pubmed: 28880890
J Virol. 2000 Jun;74(12):5516-24
pubmed: 10823857
J Virol. 2002 Oct;76(19):9920-33
pubmed: 12208969
J Virol. 1996 Feb;70(2):1223-7
pubmed: 8551584
Cell. 2002 Jan 25;108(2):283-95
pubmed: 11832217
Virology. 1998 May 25;245(1):33-46
pubmed: 9614865
Oncolytic Virother. 2014 Jul 09;3:69-82
pubmed: 27512664
J Virol. 2004 Feb;78(4):1882-92
pubmed: 14747553
Cell Microbiol. 2017 Dec;19(12):
pubmed: 28672089
Virology. 1994 Jun;201(2):303-11
pubmed: 8184540
Nature. 1963 Jun 1;198:834-7
pubmed: 13959750
Science. 1959 Nov 20;130(3386):1387-9
pubmed: 14440555
J Biol Chem. 2004 Feb 6;279(6):4394-403
pubmed: 14613938
J Virol. 1997 Oct;71(10):7728-35
pubmed: 9311857
J Virol. 2002 May;76(9):4483-96
pubmed: 11932414
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7344-7349
pubmed: 29941585
J Virol. 2001 Aug;75(16):7429-34
pubmed: 11462015
Annu Rev Biochem. 1976;45:375-408
pubmed: 786154
J Virol. 2010 Jan;84(2):867-82
pubmed: 19889754
Virology. 1969 Dec;39(4):822-31
pubmed: 5358831
J Virol. 2020 Jan 31;94(4):
pubmed: 31776267
J Virol. 2002 Aug;76(16):8285-97
pubmed: 12134034
Virology. 2000 Jun 20;272(1):16-26
pubmed: 10873745
PLoS Pathog. 2020 Sep 21;16(9):e1008803
pubmed: 32956403
World J Methodol. 2016 Mar 26;6(1):25-42
pubmed: 27019795
Nat Struct Biol. 2003 Dec;10(12):1011-8
pubmed: 14608373
Arch Biochem Biophys. 1980 Jul;202(2):348-60
pubmed: 7458325
Viruses. 2015 Dec 01;7(12):6251-78
pubmed: 26633466
J Virol. 1989 Nov;63(11):4850-6
pubmed: 2552158
J Virol. 2018 Jul 17;92(15):
pubmed: 29769334
PLoS One. 2012;7(10):e48064
pubmed: 23110175
J Virol. 2009 Jun;83(11):5659-70
pubmed: 19297468
J Biol Chem. 2002 Jul 5;277(27):24609-17
pubmed: 11986312
Ann N Y Acad Sci. 1962 Nov 30;101:461-5
pubmed: 13974842
J Virol. 2009 Oct;83(19):9630-40
pubmed: 19640986
J Virol. 2012 Apr;86(7):3466-73
pubmed: 22278245
J Virol. 2012 Oct;86(20):10979-87
pubmed: 22837214
Virology. 2018 May;518:77-86
pubmed: 29455064
J Virol. 1979 Jun;30(3):863-74
pubmed: 480468
Virol J. 2004 Sep 23;1:6
pubmed: 15507160
Mol Cancer Ther. 2016 May;15(5):767-73
pubmed: 27197256
J Virol. 2013 Dec;87(23):12967-79
pubmed: 24067959

Auteurs

Wan Kong Wynton Yip (WKW)

Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.

Francisca Cristi (F)

Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.

Georgi Trifonov (G)

Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.

Nashae Narayan (N)

Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.

Mark Kubanski (M)

Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.

Maya Shmulevitz (M)

Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada shmulevi@ualberta.ca.

Classifications MeSH